Table 5. Recommendation and quality of evidence table for HIV nucleoside reverse transcriptase inhibitors and anti-malarial drugs.
| NRTIs | |||||||
|---|---|---|---|---|---|---|---|
| ABC | ddI | FTC | 3TC | d4T | TDF | ZDV | |
| Amodiaquine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | □ (4) |
| Artemether | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Artesunate | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Atovaquone | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | □ (3)* |
| Chloroquine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Clindamycin | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Dihydroartemisinin | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Doxycycline | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Lumefantrine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Mefloquine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Piperaquine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Primaquine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | □ (4) |
| Proguanil | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Pyronaridine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | □ (4) |
| Quinine | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) | ◊ (4) |
| Pyrimethamine/sulfadoxine | ◊ (4) | ◊ (4) | ⌂ (4) | ⌂ (4) | ◊ (4) | ◊ (4) | ⌂ (4)$ |
Notes: Numbers 1–4 correspond to quality of evidence (Table 1); coloured symbols correspond to the recommendation (Table 2); * denotes drug pairs where data are available (S1 Table); $ denotes drug pairs where data are available, however a recommendation has been made based on manufacturer summaries of product characteristics